A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield

Science

Volumn 334, Issue 6059, 2011, Pages 1097-1103

  Pejchal, Robert ^a   Doores, Katie J ^a,b   Walker, Laura M ^a   Khayat, Reza ^a   Huang, Po Ssu ^c   Wang, Sheng Kai ^a   Stanfield, Robyn L ^a   Julien, Jean Philippe ^a   Ramos, Alejandra ^a   Crispin, Max ^d   Depetris, Rafael ^e   Katpally, Umesh ^f   Marozsan, Andre ^f   Cupo, Albert ^f   Maloveste, Sebastien ^g   Liu, Yan ^h   McBride, Ryan ^a   Ito, Yukishige ⁱ   Sanders, Rogier W ^e,j   Ogohara, Cassandra ^c   Paulson, James C ^a   Feizi, Ten ^h   Scanlan, Christopher N ^d   Wong, Chi Huey ^a   Moore, John P ^e   Olson, William C ^f   Ward, Andrew B ^a   Poignard, Pascal ^a,k   Schief, William R ^a,c   Burton, Dennis R ^a,b   Wilson, Ian A ^a   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f A Subsidiary of Lantheus Holdings   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ RIKEN   (Japan)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MANNOSE; NEUTRALIZING ANTIBODY; PGT 127; PGT 128; UNCLASSIFIED DRUG;

ANTIBODY; CRYSTAL STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR ANALYSIS; NEUTRALIZATION; POLYMER; PROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS LINKING; CRYSTAL STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN GLYCOSYLATION; VIRUS ENVELOPE;

EID: 82255179322     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1213256     Document Type: Article

References (43)

1. P. D. Kwong et al., Nature 393, 648 (1998).
2. R. Wyatt, J. Sodroski, Science 280, 1884 (1998).
3. E. J. Toone, Curr. Opin. Struct. Biol. 4, 719 (1994).
4. D. A. Calarese et al., Science 300, 2065 (2003).
5. L. M. Walker et al., Nature 477, 466 (2011).
6. L. M. Walker et al., Science 326, 285 (2009).
7. X. Wu et al., Science 329, 856 (2010).
8. X. Wu et al., Science 333, 1593 (2011).
9. J. M. Binley et al., J. Virol. 78, 13232 (2004).
10. I. A. Wilson, R. L. Stanfield, Nat. Struct. Biol. 2, 433 (1995).
11. P. C. Wilson et al., J. Exp. Med. 187, 59 (1998).
12. J. C. Krause et al., mBio 2, e00345-10 (2011).
13. It has been shown that a three-amino acid insertion in the heavy-chain CDR H2 of the influenza virus-specific mAb 2D1 rearranges the antibody-combining site and enhances neutralization potency (12), demonstrating that somatically introduced amino acid insertions may be a conserved molecular mechanism for increasing antibody potency against viral pathogens.
14. -/- HEK 293S cells to mimic the oligomannose-type glycosylation of that domain within intact gp120.
15. 325 peptide bond. Also, similar to many other bnmAbs to HIV, the PGT 128 CDR H3 loop is relatively long (19 amino acids), although not the longest seen to date for human Abs [31 or 32 residues for the PGT 140 series (5)].
16. R. L. Stanfield, M. K. Gorny, C. Williams, S. Zolla-Pazner, I. A. Wilson, Structure 12, 193 (2004).
17. T. Zhou et al., Science 329, 811 (2010).
18. S. Beddows et al., AIDS Res. Hum. Retroviruses 22, 569 (2006).
19. J. M. Binley et al., J. Virol. 74, 627 (2000).
20. J. M. Binley et al., J. Virol. 76, 2606 (2002).
21. R. W. Sanders et al., J. Virol. 76, 8875 (2002).
22. A. Harris et al., Proc. Natl. Acad. Sci. U.S.A. 108, 11440 (2011).
23. The HIV-1 664G trimer is based on the clade A strain KNH1144 and incorporates stabilizing mutations A501C, T605C, and I559P. We have previously shown that trimers incorporating these stabilizing mutations are competent to undergo CD4-induced conformational changes akin to those observed in the native trimer (22).
24. P. W. Parren, D. R. Burton, Adv. Immunol. 77, 195 (2001).
25. P. W. Parren et al., J. Virol. 72, 3512 (1998).
26. P. Roben et al., J. Virol. 68, 4821 (1994).
27. Q. J. Sattentau, J. P. Moore, J. Exp. Med. 182, 185 (1995).
28. M. Pancera, R. Wyatt, Virology 332, 145 (2005).
29. JR-FL is the only HIV isolate that has been shown to express a high proportion of fully cleaved Env trimers on the surface of transfected cells and was, therefore, selected for binding studies.
30. J. Liu, A. Bartesaghi, M. J. Borgnia, G. Sapiro, S. Subramaniam, Nature 455, 109 (2008).
31. P. J. Klasse, Virology 369, 245 (2007).
32. J. S. Klein, P. J. Bjorkman, PLoS Pathog. 6, e1000908 (2010).
33. J. S. Klein et al., Proc. Natl. Acad. Sci. U.S.A. 106, 7385 (2009).
34. C. Ansarah-Sobrinho, S. Nelson, C. A. Jost, S. S. Whitehead, T. C. Pierson, Virology 381, 67 (2008).
35. S. P. Layne et al., Virology 189, 695 (1992).
36. J. M. Le Doux, H. E. Davis, J. R. Morgan, M. L. Yarmush, Biotechnol. Bioeng. 63, 654 (1999).
37. K. A. Dowd, C. A. Jost, A. P. Durbin, S. S. Whitehead, T. C. Pierson, PLoS Pathog. 7, e1002111 (2011).
38. C. R. Ruprecht et al., J. Exp. Med. 208, 439 (2011).
39. H. Haim et al., PLoS Pathog. 5, e1000360 (2009).
40. E. S. Gray et al.; and the CAPRISA002 Study Team, J. Virol. 85, 4828 (2011).
41. L. M. Walker et al., PLoS Pathog. 6, e1001028 (2010).
42. H. Tang et al., J. Virol., 85, 9286 (2011).
43. A. Nandi et al.; NIAID Center for HIV/AIDS Vaccine Immunology, Virology 396, 339 (2010).